Par Pharmaceutical Pleads Guilty To Off-Label Promotion, Pays $45M In Settlements

Par Pharmaceutical Pleads Guilty To Off-Label Promotion, Pays $45M In Settlements

NEWARK, N.J. - Par Pharmaceutical Cos. Inc. on March 5 pleaded guilty to misbranding its Megace ES anti-wasting drug by promoting it for off-label use in geriatric patients and will pay $45 million to resolve criminal and civil allegations, according to the U.S. Attorney's Office for the District of New Jersey (United States of America v. Par Pharmaceutical Companies, Inc., No. n/a, D. N.J.).

Find full version on lexis Advance®
Access this news story on lexis.com®